Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Anna Maria Di Giacomo, Michele Maio, Paola Queirolo et al.|Annals of Oncology|2014

Cited by 139